All-change for Novartis management in reshuffle

As part of the management shake-up at Swiss drug major Novartis (see page 10): Andrin Oswald, current chief executive of the Swiss company's subsidiary Speedel, will replace new chief operating officer Jorg Reinhardt as head of the vaccines unit; George Gunn, now head of the firm's animal health division will replace Thomas Ebeling, who has left the firm, as chief of consumer health care; Andreas Rummelt, head of the Sandoz generics division, will now head quality assurance and be replaced by Jeff George; and David Epstein has been moved from the oncology division to molecular diagnostics.